panitumumab Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group
Sitenames

Any (1)

Phase 2 (1)

Interventional (1)

National Cancer Institute, Naples (1)

No (1)

No (1)

Adult (18+) (1)

di (1)
fondazion (1)
g (1)
ircc (1)
istituto (1)
napoli (1)
nazional (1)
pascal (1)
tumori (1)

I am/have/had

I am/have/hadcancer

I am/have/hadmeasurable disease

I am/have/hadmetastasis

I am/have/hadmetastatic colorectal cancer

I am/have/hadcolorectal cancer

I am/have/hadneutrophil count

I am/have/hadliver metastasis

I am/have/hadfolfiri regimen

I am/have/hadadjuvant chemotherapy

I am/have/hadstage iv colorectal cancer

I am/have/hadBRAF

I am/have/hadabsolute neutrophil count

added new label for I am/have/had

more

I am looking for

I am looking forpanitumumab

I am looking foradjuvant

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 2
For Seniors
For adults
Recruiting in 100s
Interventional Study
all
Recruiting

Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer

The investigators hypothesize that intermittent first-line Panitumumab plus FOLFIRI is effective as the same regimen given continuously, in unresectable metastatic RAS and BRAF wild type colorectal cancer patients.

neutrophil count

adjuvant

liver metastasis

cancer

metastasis

0 views
16 Feb, 2024
1 location

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.